Abbott Laboratories Slides Near 52-Week Low as Selling Pressure Persists
By TrendSpider Editor
Abbott Laboratories shares slipped another 0.45% on Monday, May 18, 2026, settling at $84.51 as the stock continues to hover dangerously close to its 52-week low of $81.97. The move adds to what has been a prolonged period of weakness for the medical device and diagnostics giant, with the stock sitt
Abbott Laboratories Slides Near 52-Week Low as Selling Pressure Persists
Abbott Laboratories shares slipped another 0.45% on Monday, May 18, 2026, settling at $84.51 as the stock continues to hover dangerously close to its 52-week low of $81.97. The move adds to what has been a prolonged period of weakness for the medical device and diagnostics giant, with the stock sitting just $2.54 above its yearly floor and a staggering 39% below its 52-week high of $139.05. With the stock compressed near multi-year lows, investors are watching closely for any catalyst that might either stabilize the name or push it to fresh lows.
Key Drivers of the ABT Stock Move
- Main Catalyst: ABT is flagging as a near-52-week-low mover, with shares currently at $84.51, only $2.54 above the 52-week low of $81.97. The stock traded in a range of $84.135 to $86.475 in the prior session, reflecting tight, compressed price action with little conviction to the upside.
- Bull Case: At $84.51, ABT is trading at a deep discount relative to its 52-week high of $139.05, representing a nearly 39% drawdown from peak levels. For value-oriented investors, this level of compression in a large-cap healthcare name with diversified revenue streams could represent a long-term entry opportunity if the fundamental thesis remains intact.
- Bear Case: The inability to hold above the prior session high of $86.475, combined with a continued drift toward the 52-week low of $81.97, signals persistent distribution. A break below $81.97 would mark a new 52-week low and could accelerate selling as technical support gives way, with no clear floor visible on the chart beneath current levels.
The forward setup for ABT is cautious at best. The stock's price structure reflects a name in a well-established downtrend, with lower highs forming well below the $139.05 peak reached over the past year. The narrow prior-session range between $84.135 and $86.475 suggests the market has yet to find aggressive buyers willing to step in at these levels. Abbott operates across diagnostics, medical devices, nutrition, and established pharmaceuticals, giving it diversified revenue exposure, but that breadth has not been enough to arrest the decline. Until the stock can reclaim meaningful technical levels and show sustained buying volume, the path of least resistance remains to the downside. A close below $81.97 would be a significant technical event worth monitoring closely in the sessions ahead.
ABT Seasonality
Mid-May has historically been a transitional period for large-cap healthcare names, sitting between first-quarter earnings season and the summer doldrums when volume and conviction can thin out. A stock already pressing against 52-week lows during this period faces a headwind, as lighter summer trading volumes tend to favor continuation of existing trends rather than sharp reversals.
ABT Relative Performance
ABT's 0.45% decline on May 18, 2026, underscores its underperformance relative to broader healthcare sector peers. While the stock sits only 3% above its 52-week low of $81.97, the gap between current price and the 52-week high of $139.05 illustrates just how significantly ABT has lagged during a period when many large-cap names have managed to hold closer to their yearly highs. The stock's compressed range and proximity to its annual floor position it as one of the weaker performers in the large-cap medical device space at this time.